NASDAQ:IMTX Immatics (IMTX) Stock Price, News & Analysis → Your $200 account credit is about to expire (From MarketBeat) (Ad) Free IMTX Stock Alerts $10.95 -0.15 (-1.35%) (As of 12:40 PM ET) Add Compare Share Share Today's Range$10.90▼$11.2250-Day Range$11.10▼$12.9452-Week Range$5.90▼$13.16Volume108,290 shsAverage Volume518,680 shsMarket Capitalization$927.03 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Immatics alerts: Email Address Immatics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside8.9% Upside$12.00 Price TargetShort InterestBearish9.91% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.17Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.65) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.40 out of 5 starsMedical Sector900th out of 939 stocksBiological Products, Except Diagnostic Industry150th out of 155 stocks 1.5 Analyst's Opinion Consensus RatingImmatics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Immatics has a forecasted upside of 8.9% from its current price of $11.02.Amount of Analyst CoverageImmatics has received no research coverage in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.91% of the outstanding shares of Immatics have been sold short.Short Interest Ratio / Days to CoverImmatics has a short interest ratio ("days to cover") of 16.7, which indicates bearish sentiment.Change versus previous monthShort interest in Immatics has recently increased by 4.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldImmatics does not currently pay a dividend.Dividend GrowthImmatics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMTX. Previous Next 4.0 News and Social Media Coverage News SentimentImmatics has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Immatics this week, compared to 1 article on an average week.Search Interest2 people have searched for IMTX on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Immatics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immatics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.30% of the stock of Immatics is held by insiders.Percentage Held by Institutions64.41% of the stock of Immatics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immatics are expected to grow in the coming year, from ($1.65) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immatics is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immatics is -8.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmatics has a P/B Ratio of 3.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> About Immatics Stock (NASDAQ:IMTX)Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Read More IMTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMTX Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comImmatics Expected to Earn Q1 2024 Earnings of ($0.18) Per Share (NASDAQ:IMTX)March 21, 2024 | investorplace.comIMTX Stock Earnings: Immatics Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | MarketBeat (Ad)Your $200 account credit is about to expireUpdate to MarketBeat All Access and Save $300 on Your Annual SubscriptionMarch 21, 2024 | globenewswire.comImmatics Announces Full Year 2023 Financial Results and Corporate UpdateMarch 15, 2024 | finance.yahoo.comWith 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big gunsMarch 10, 2024 | seekingalpha.comCantor sees strong year ahead for oncology M&AMarch 10, 2024 | msn.comCantor Fitzgerald sees strong year ahead for oncology M&AMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immatics on Promising TCR-Based Cancer Therapies and Strategic PartnershipsMarch 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 28, 2024 | seekingalpha.comEditas Medicine: Several Catalysts For Reni-Cel In 2024 Make This A Must WatchFebruary 6, 2024 | uk.yahoo.comBolton TV star to 'go back to Fernandos one last time' as he spreads the loveFebruary 3, 2024 | finance.yahoo.comImmatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last yearFebruary 3, 2024 | seekingalpha.comImmatics: Pioneering TCR Therapies In The Fight Against CancerJanuary 17, 2024 | msn.comImmatics commences public offering of sharesJanuary 17, 2024 | finance.yahoo.comImmatics Announces Pricing of $175 Million Public OfferingJanuary 17, 2024 | finance.yahoo.comImmatics Announces Proposed Public OfferingNovember 20, 2023 | markets.businessinsider.comPositive Clinical Progress and Promising Pipeline Underpin Buy Rating for Immatics (IMTX): An Analysis of Graig Suvannavejh’s RecommendationNovember 16, 2023 | markets.businessinsider.comImmatics: Strong Buy Rating Supported by Promising Clinical Results and Upcoming CatalystsNovember 14, 2023 | markets.businessinsider.comImmatics Announces Third Quarter 2023 Financial Results and Business UpdateNovember 8, 2023 | finanznachrichten.deImmatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 TrialNovember 6, 2023 | finance.yahoo.comImmatics (IMTX) Moves 23.2% Higher: Will This Strength Last?November 3, 2023 | nasdaq.comCantor Fitzgerald Initiates Coverage of Immatics N.V (IMTX) with Overweight RecommendationOctober 24, 2023 | finance.yahoo.comImmatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T MonotherapyOctober 12, 2023 | msn.comDown -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)October 9, 2023 | seekingalpha.comAnalyzing Immatics' Multi-Faceted Investment CaseSeptember 21, 2023 | finance.yahoo.comIMTX Oct 2023 10.000 putSeptember 11, 2023 | marketwatch.comImmatics shares rise on Moderna cancer collaborationSee More Headlines Receive IMTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immatics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/28/2024Next Earnings (Estimated)5/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:IMTX CUSIPN/A CIK1809196 Webwww.immatics.com Phone4.97072E+12FaxN/AEmployees433Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+8.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-104,980,000.00 Net Margins-179.67% Pretax Margin-179.63% Return on Equity-43.58% Return on Assets-22.38% Debt Debt-to-Equity RatioN/A Current Ratio2.87 Quick Ratio2.87 Sales & Book Value Annual Sales$54.00 million Price / Sales17.40 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book3.85Miscellaneous Outstanding Shares84,656,000Free FloatN/AMarket Cap$939.68 million OptionableOptionable Beta0.69 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Harpreet Singh Ph.D. (Age 49)CEO, MD, Member of Management Board & Executive Director Comp: $902kDr. Toni Weinschenk Ph.D. (Age 50)Co-Founder & Chief Innovation Officer Mr. Arnd Christ MBA (Age 58)Chief Financial Officer Mr. Steffen Walter Ph.D. (Age 47)Chief Operations Officer Dr. Carsten Reinhardt M.D. (Age 57)Ph.D., Chief Development Officer Dr. Rainer Kramer Ph.D. (Age 59)Chief Business Officer & Site Head Munich Mr. Cedrik M. Britten M.D. (Age 48)Chief Medical Officer Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory BoardMr. Kristijan LasicDirector of AccountingDr. Emmanuelle Schuler M.B.A.Ph.D., VP of Administration & Operations and US Site HeadMore ExecutivesKey CompetitorsREGENXBIONASDAQ:RGNXCARGO TherapeuticsNASDAQ:CRGXRelay TherapeuticsNASDAQ:RLAYKyverna TherapeuticsNASDAQ:KYTXBioCryst PharmaceuticalsNASDAQ:BCRXView All CompetitorsInstitutional OwnershipWellington Management Group LLPBought 747,772 shares on 3/5/2024Ownership: 7.504%Goldman Sachs Group Inc.Bought 1,183,860 shares on 3/1/2024Ownership: 1.830%Price T Rowe Associates Inc. MDBought 719,634 shares on 2/16/2024Ownership: 2.757%Sphera Funds Management LTD.Bought 3,938 shares on 2/15/2024Ownership: 0.734%Virtus ETF Advisers LLCBought 1,184 shares on 2/15/2024Ownership: 0.011%View All Institutional Transactions IMTX Stock Analysis - Frequently Asked Questions Should I buy or sell Immatics stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Immatics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" IMTX shares. View IMTX analyst ratings or view top-rated stocks. What is Immatics' stock price target for 2024? 2 analysts have issued 12 month price objectives for Immatics' stock. Their IMTX share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 8.9% from the stock's current price. View analysts price targets for IMTX or view top-rated stocks among Wall Street analysts. How have IMTX shares performed in 2024? Immatics' stock was trading at $10.53 at the beginning of 2024. Since then, IMTX stock has increased by 4.7% and is now trading at $11.02. View the best growth stocks for 2024 here. When is Immatics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024. View our IMTX earnings forecast. How were Immatics' earnings last quarter? Immatics (NASDAQ:IMTX) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.13. The firm earned $7.60 million during the quarter, compared to analysts' expectations of $13.28 million. Immatics had a negative net margin of 179.67% and a negative trailing twelve-month return on equity of 43.58%. What ETFs hold Immatics' stock? ETFs with the largest weight of Immatics (NASDAQ:IMTX) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). What other stocks do shareholders of Immatics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immatics investors own include Advanced Micro Devices (AMD), Chimerix (CMRX), Datadog (DDOG), Forte Biosciences (FBRX), Great Panther Mining (GPL), Idera Pharmaceuticals (IDRA) and Immunic (IMUX). Who are Immatics' major shareholders? Immatics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (7.50%), Price T Rowe Associates Inc. MD (2.76%), Price T Rowe Associates Inc. MD (2.76%), Vestal Point Capital LP (2.48%), Goldman Sachs Group Inc. (1.83%) and Goldman Sachs Group Inc. (1.83%). How do I buy shares of Immatics? Shares of IMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMTX) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.